InvestorsObserver
×
News Home

Is Puma Biotechnology Inc (PBYI) Stock a Bad Value Tuesday?

Tuesday, March 21, 2023 02:26 PM | InvestorsObserver Analysts

Mentioned in this article

Is Puma Biotechnology Inc (PBYI) Stock a Bad Value Tuesday?

Puma Biotechnology Inc (PBYI) is near the top in its sector according to InvestorsObserver. PBYI gets an overall rating of 72. That means it scores higher than 72% of stocks. Puma Biotechnology Inc gets a 78 rank in the Healthcare sector. Healthcare is number 3 out of 11 sectors.

Overall Score - 72
PBYI has an Overall Score of 72. Find out what this means to you and get the rest of the rankings on PBYI!

What do These Ratings Mean?

Searching for the best stocks to invest in can be difficult. There are thousands of options and it can be confusing on what actually constitutes a great value. *Investors Observer* allows you to choose from eight unique metrics to view the top industries and the best performing stocks in that industry. A score of 72 would rank higher than 72 percent of all stocks. This ranking system incorporates numerous factors used by analysts to compare stocks in greater detail. This allows you to find the best stocks available in the healthcare sector with relative ease. These percentile-ranked scores using both fundamental and technical analysis give investors an easy way to view the attractiveness of specific stocks. Stocks with the highest scores have the best evaluations by analysts working on Wall Street.

What's Happening With Puma Biotechnology Inc Stock Today?

Puma Biotechnology Inc (PBYI) stock is down -0.81% while the S&P 500 has gained 0.81% as of 2:26 PM on Tuesday, Mar 21. PBYI is lower by -$0.02 from the previous closing price of $2.47 on volume of 243,682 shares. Over the past year the S&P 500 is down -10.71% while PBYI is lower by -20.71%. PBYI earned $0.00 a per share in the over the last 12 months, giving it a price-to-earnings ratio of 61250. Click Here to get the full Stock Report for Puma Biotechnology Inc stock.

You May Also Like

Get the InvestorsObserver App

InvestorsObserver App
iOS App Android App